4Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol, 1998,32 (Suppl 1 ) : S22--30.
5Sia YT, Lapointe N, Parker TG, et al. Beneficial effects of longterm use of the antioxidant probucol in heart failure in the rat. Circulation,2002,105 : 2549--2555.
6Iwai-Kanai E, Hasegawa K, Araki M, et al. Alpha-and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation, 1999, 100:305--311.
7Lotze U, Heinke S, Fritzenwanger M, et al. Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. J Cardiovasc Pharmacol, 2002, 39: 576--589.
8Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system. Atrial natrial natriuretie peptide and brain natriuretie peptide. J Clin Invest, 1991, 87: 1402-1412.
9Maisel AS, Koon J, Kfishnaswamy P, et al. Utility of B-natfiuretie peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventficular dysfunction. Am Heart J, 2001, 141:367-374,.
10Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism ofsecretion of B-type natfiuretie peptide in comparison with A-type natriuretiepeptide in normal subjects and patients with heart failure. Circulation,1994, 90: 195-203.
